S.N. Movchan, the Vice-Governor of St. Petersburg, and V. I. Vlasov, the President of Novartis Group in Russia, launched the commercial manufacturing of Ketonal® DUO at Novartis Neva plant in St. Petersburg.
The first lot of locally manufactured Ketonal® DUO (a trade mark of Sandoz division) designed for the treatment of various inflammatory processes will be available to Russian patients as early as in the first half of 2018.
Sergey Movchan said that Novartis Neva is a modern and innovative pharmaceutical enterprise. The manufacturing of medicinal products at this facility will help to address the important objective of import substitution and provision of necessary medicines to Russia.
“This is an important event for us and yet another planned step in the implementation of the long-term investment program of Novartis, the main goal of which is to improve the availability of high quality health care to Russians by localizing the manufacturing and introducing innovative technologies. In addition, we view the launch of commercial manufacturing at the company-owned plant in St. Petersburg as a practical contribution to the implementation of Pharma 2020 state program aimed at establishing a world-class pharmaceutical industry in Russia,” said V.I. Vlasov.
In the future, Novartis Neva will continue to gradually increase its output in order to ensure the availability of company products in the Russian market. Currently, the company is actively working on transferring, from its foreign sites, the innovative technologies for a number of drugs, two of which have been already approved by the Russian Ministry of Health and three others are in the process of registration.